343 related articles for article (PubMed ID: 22882073)
1. Novel targeted therapies and combinations for the treatment of multiple myeloma.
Agarwal A; Mahadevan D
Cardiovasc Hematol Disord Drug Targets; 2013 Mar; 13(1):2-15. PubMed ID: 22882073
[TBL] [Abstract][Full Text] [Related]
2. Contemporary drug therapies for multiple myeloma.
de la Puente P; Azab AK
Drugs Today (Barc); 2013 Sep; 49(9):563-73. PubMed ID: 24086952
[TBL] [Abstract][Full Text] [Related]
3. Multiple myeloma: Updates for pharmacists in the treatment of relapsed and refractory disease.
Ashjian E; Redic K
J Oncol Pharm Pract; 2016 Apr; 22(2):289-302. PubMed ID: 25694345
[TBL] [Abstract][Full Text] [Related]
4. CD38 Monoclonal Antibody Therapies for Multiple Myeloma.
Wong SW; Comenzo RL
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):635-45. PubMed ID: 26443328
[TBL] [Abstract][Full Text] [Related]
5. Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma.
Pantani L; Brioli A; Tacchetti P; Zannetti BA; Mancuso K; Rocchi S; Martello M; Rizzello I; Terragna C; Zamagni E; Cavo M
Expert Rev Hematol; 2016 Mar; 9(3):315-23. PubMed ID: 26634945
[TBL] [Abstract][Full Text] [Related]
6. Molecular mechanisms of effectiveness of novel therapies in multiple myeloma.
Bianchi G; Ghobrial IM
Leuk Lymphoma; 2013 Feb; 54(2):229-41. PubMed ID: 22897729
[TBL] [Abstract][Full Text] [Related]
7. Resistance to proteasome inhibitors and other targeted therapies in myeloma.
Wallington-Beddoe CT; Sobieraj-Teague M; Kuss BJ; Pitson SM
Br J Haematol; 2018 Jul; 182(1):11-28. PubMed ID: 29676460
[TBL] [Abstract][Full Text] [Related]
8. An update in treatment options for multiple myeloma in nontransplant eligible patients.
Broijl A; Sonneveld P
Expert Opin Pharmacother; 2015; 16(13):1945-57. PubMed ID: 26245702
[TBL] [Abstract][Full Text] [Related]
9. New pharmacotherapy options for multiple myeloma.
Mina R; Cerrato C; Bernardini A; Aghemo E; Palumbo A
Expert Opin Pharmacother; 2016; 17(2):181-92. PubMed ID: 26684262
[TBL] [Abstract][Full Text] [Related]
10. Novel investigational drugs active as single agents in multiple myeloma.
D'Agostino M; Salvini M; Palumbo A; Larocca A; Gay F
Expert Opin Investig Drugs; 2017 Jun; 26(6):699-711. PubMed ID: 28448171
[TBL] [Abstract][Full Text] [Related]
11. Strategy for the treatment of multiple myeloma utilizing monoclonal antibodies: A new era begins.
Magarotto V; Salvini M; Bonello F; Bringhen S; Palumbo A
Leuk Lymphoma; 2016; 57(3):537-56. PubMed ID: 26445358
[TBL] [Abstract][Full Text] [Related]
12. Deacetylase inhibitors: an advance in myeloma therapy?
Laubach JP; San-Miguel JF; Hungria V; Hou J; Moreau P; Lonial S; Lee JH; Einsele H; Alsina M; Richardson PG
Expert Rev Hematol; 2017 Mar; 10(3):229-237. PubMed ID: 28076695
[TBL] [Abstract][Full Text] [Related]
13. Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma.
Podar K; Pecherstorfer M
Expert Opin Pharmacother; 2017 Aug; 18(11):1061-1079. PubMed ID: 28604120
[TBL] [Abstract][Full Text] [Related]
14. [Novel targeted therapy in multiple myeloma].
Izumi T
Nihon Rinsho; 2014 Jun; 72(6):1089-93. PubMed ID: 25016809
[TBL] [Abstract][Full Text] [Related]
15. Targeting signaling pathways in multiple myeloma: Pathogenesis and implication for treatments.
Hu J; Hu WX
Cancer Lett; 2018 Feb; 414():214-221. PubMed ID: 29174802
[TBL] [Abstract][Full Text] [Related]
16. Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.
Podar K; Jager D
Curr Cancer Drug Targets; 2017; 17(9):782-805. PubMed ID: 28201977
[TBL] [Abstract][Full Text] [Related]
17. Emerging therapies in multiple myeloma.
El-Amm J; Tabbara IA
Am J Clin Oncol; 2015 Jun; 38(3):315-21. PubMed ID: 23934133
[TBL] [Abstract][Full Text] [Related]
18. Advances in targeted therapy for the treatment of patients with relapsed/refractory multiple myeloma.
Le Ray E; Jagannath S; Palumbo A
Expert Rev Hematol; 2016 Jan; 9(1):91-105. PubMed ID: 26558304
[TBL] [Abstract][Full Text] [Related]
19. A look backward and forward in the regulatory and treatment history of multiple myeloma: Approval of novel-novel agents, new drug development, and longer patient survival.
Kazandjian D; Landgren O
Semin Oncol; 2016 Dec; 43(6):682-689. PubMed ID: 28061986
[TBL] [Abstract][Full Text] [Related]
20. [New drugs in the treatment of multiple myeloma].
Oriol A; Motlló C
Med Clin (Barc); 2014 Sep; 143(6):268-74. PubMed ID: 24342015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]